Funding for this research was provided by:
National Natural Science Foundation of China (81302364)
Received: 18 June 2019
Accepted: 31 October 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: The research had been supported by the Ethics Committee of Shengjing Hospital. Relevant clinical information was gathered from patients’ records and informed written consent had been gained. The anaplastic thyroid carcinoma cell lines 8305c and FRO were obtained from Cell bank of typical culture preservation Committee of Chinese Academy of Sciences, and did not require ethics approval for their use in this study.
: Not applicable.
: The authors declare that they have no competing interests.